%0 Journal Article
%T Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification
%A Wang, Chunguo
%A Xu, Feng
%A Shen, Jianfei
%A Zhang, Linna
%A Zhang, Jian
%A Jin, Jiang
%A Ampollini, Luca
%A Schil, Paul van
%A Kimura, Hideharu
%A Grossi, Francesco
%A Suda, Kenichi
%A Zhang, Bo
%A Ma, Dehua
%A AME Lung Cancer Collaborative Group, written on behalf of the
%J Journal of Thoracic Disease
%D 2018
%B 2018
%9 
%! Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification
%K 
%X In the past, the optimal first-line treatment of advanced non-small cell lung cancer (NSCLC) patients with wild-type for epidermal growth factor receptor (wt-EGFR) has been platinum-based chemotherapy doublets (1,2). More recently, clinicians have adopted immunotherapy with check-point inhibitors alone, in PD-L1 strong positive, or combined with chemotherapy independently to PD-L1 expression (3).
%U https://jtd.amegroups.org/article/view/24888
%V 10
%N 11
%P E779-E783
%@ 2077-6624